跳转至内容
Merck
CN

46713

Supelco

利福平

VETRANAL®, analytical standard

别名:

3-(4-甲基-1-哌嗪基亚胺甲基)利福霉素SV, 利米定, 甲哌利福霉素

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C43H58N4O12
化学文摘社编号:
13292-46-1
分子量:
822.94
Beilstein:
5723476
EC 号:
236-312-0
MDL编号:
MFCD00151389
UNSPSC代码:
41116107
PubChem化学物质编号:
329757224
NACRES:
NA.24

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

analytical standard

质量水平

200

产品线

VETRANAL®

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

抗生素抗菌谱

mycobacteria

应用

clinical
forensics and toxicology
pharmaceutical (small molecule)

包装形式

neat

作用机制

protein synthesis | interferes

储存温度

2-8°C

SMILES字符串

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

InChI key

JQXXHWHPUNPDRT-WLSIYKJHSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Chemical structure: macrolide

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

生化/生理作用

作用方式：通过与RNA聚合酶的β-亚基结合抑制RNA合成的起始。
抑制DNA和蛋白质组装成成熟的病毒颗粒。

法律信息

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H302

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCB0045
BCBX5601

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Samy Figueiredo et al.
Antimicrobial agents and chemotherapy, 53(6), 2657-2659 (2009-03-25)
Two clonally related Acinetobacter baumannii isolates, A1 and A2, were obtained from the same patient. Isolate A2, selected after an imipenem-containing treatment, showed reduced susceptibility to carbapenems. This resistance pattern was related to insertion of the ISAba1 element upstream of
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
Jossy van den Boogaard et al.
Antimicrobial agents and chemotherapy, 53(3), 849-862 (2008-12-17)
Justin J Wilkins et al.
Antimicrobial agents and chemotherapy, 52(6), 2138-2148 (2008-04-09)
This article describes the population pharmacokinetics of rifampin in South African pulmonary tuberculosis patients. Three datasets containing 2,913 rifampin plasma concentration-time data points, collected from 261 South African pulmonary tuberculosis patients aged 18 to 72 years and weighing 28.5 to
Daniela Baldoni et al.
Antimicrobial agents and chemotherapy, 53(3), 1142-1148 (2008-12-17)
We investigated the activity of linezolid, alone and in combination with rifampin (rifampicin), against a methicillin-resistant Staphylococcus aureus (MRSA) strain in vitro and in a guinea pig model of foreign-body infection. The MIC, minimal bactericidal concentration (MBC) in logarithmic phase
Toril Lindbäck et al.
Veterinary research, 41(1), 8-8 (2009-10-03)
Media-based bacteriological testing will fail to detect non-culturable organisms and the risk of consuming viable but non-culturable (VBNC) Listeria monocytogenes is unknown. We have here studied whether L. monocytogenes obtained from seafoods, processing environment and clinical cases enter the VBNC
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持